<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1846">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04372082</url>
  </required_header>
  <id_info>
    <org_study_id>2020_40</org_study_id>
    <secondary_id>2020-002188-72</secondary_id>
    <nct_id>NCT04372082</nct_id>
  </id_info>
  <brief_title>Hydroxychloroquine or Diltiazem-Niclosamide for the Treatment of COVID-19</brief_title>
  <acronym>HYdILIC</acronym>
  <official_title>Efficacy of HYdroxychloroquine and DILtiazem-nIClosamide Combination for the Treatment of Non-severe Forms of SARS-CoV2 Infection in Patients With Co-morbidities: Multicenter, Randomized, Open-labeled Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>I-site University Lille North Europe</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      No optimal antiviral intervention has been yet validated to treat COVID-19 disease.
      Comorbidities, such as older age, obesity, diabetes, history of cardiovascular diseases are
      associated with poor prognosis.

      This study aims to evaluate the efficacy of two experimental antiviral treatments, compared
      to standard of care (SOC), to prevent clinical worsening, hospitalization or death at day 14
      in adults with documented SARS-CoV-2 infection, asymptomatic or with symptoms lasting less
      than 8 days, and associated comorbidities without any severity criteria of the disease at
      inclusion.

      Participants will be randomized to receive SOC alone or SOC + hydroxychloroquine 200 mg three
      times a day during 10 days or SOC + association of niclosamide 2 g at J1 then 500 mg two
      times a day with diltiazem 60 mg three times a day during 10 days. Efficacy and tolerance of
      each treatments will be compared across the three treatment groups during the 28 days of
      follow-up.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>death</measure>
    <time_frame>At day 14</time_frame>
    <description>Composite criteria</description>
  </primary_outcome>
  <primary_outcome>
    <measure>clinical worsening (composite criteria)</measure>
    <time_frame>At day 14</time_frame>
    <description>clinical worsening defined by at least one of the NEWS score item &gt; 2 (temperature &gt;39,1°C or&lt;35°C, cardiac rate &gt;111 or ≤40 bpm, respiratory rate &gt; 21 or ≤8 cycles par minute, SaO2 ≤ 93% room air (if its measure is available),need of oxygen</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assisted-ventilation and/or hospitalization (composite criteria)</measure>
    <time_frame>At day 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>National Early Warning Score (NEWS)</measure>
    <time_frame>at day 3, day 8, day 14 day 28</time_frame>
    <description>clinical state as reflected by NEWS scoring, the clinical state of the patient regarding respiratory state as defined by the NEWS scoring system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative incidence of hospitalizations</measure>
    <time_frame>at day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative incidence of the use of oxygen therapy, non-invasive ventilation or invasive ventilation ( composite criteria)</measure>
    <time_frame>at day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>at day 14 and at day 28</time_frame>
    <description>Number of patients death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative incidence of viral shedding on SARS-CoV-2 rt-PCR on nasopharyngeal swab;</measure>
    <time_frame>at day 3, day 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse drug reactions</measure>
    <time_frame>during study, up to 28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Sars-CoV2</condition>
  <arm_group>
    <arm_group_label>standard of care (SOC)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SOC + Hydroxychloroquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SOC + Diltiazem-Niclosamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of care (SOC)</intervention_name>
    <description>SOC procedures including self-monitoring and medical follow-up of clinical signs and if necessary any other symptomatic treatment (paracetamol, antibiotics, steroids, oxygen…) during the whole study duration</description>
    <arm_group_label>SOC + Diltiazem-Niclosamide</arm_group_label>
    <arm_group_label>SOC + Hydroxychloroquine</arm_group_label>
    <arm_group_label>standard of care (SOC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>200 mg x 3 per day during 10 days in addition to SOC</description>
    <arm_group_label>SOC + Hydroxychloroquine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Association of diltiazem and niclosamide</intervention_name>
    <description>niclosamide 500 mg x 4 at J1 then 500 mg x 2 per day + diltiazem 60 mg x 3 per day during 10 days in addition to SOC</description>
    <arm_group_label>SOC + Diltiazem-Niclosamide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Positive SARS-CoV-2 test on nasopharyngeal swab

          -  Onset of symptoms &lt;8 days prior to randomization

          -  NEWS score&lt;4 AND no item ≥2

          -  At least one comorbidity among: age ≥ 70 years old, history of cardiac disease,
             diabetes, obesity, chronic kidney disease, chronic respiratory failure,
             immunosuppression, neoplasia, liver failure (stage ≥ Child-Pugh B)

          -  Fully able to understand the challenges of the trial

          -  Signed informed consent

          -  Covered by Health Insurance

        Exclusion Criteria:

        For all patients:

          -  Inability to decide to participate

          -  Pregnancy or breath feeding

          -  Hypersensitivity to any of the test drugs

          -  stage 4 or 5 chronic kidney disease (DFG &lt;30 mL/min/1.73 m²)

        For hydroxychloroquine arm:

          -  Long QT syndrome or QTc space &gt;500 ms

          -  Treatment with piperazine, halofantrine, dasatinib, nilotinib, citalopram,
             escitalopram, hydroxyzine, domperidone

          -  Hepatic porphyria, retinopathy, known glucose-6-phosphate dehydrogenase deficiency,

          -  Heart rate &lt;50/min

          -  hypokaliemia &lt; 3.5 mmol/L

        For diltiazem arm:

          -  Heart rate&lt;40/min

          -  Sinus bradycardia, second- or third-degree atrioventricular block

          -  Left heart insufficiency with pulmonary stasis

          -  Treatment with dantrolene, pimozide, dihydroergotamine, ergotamine, nifedipine,
             ivabradine, esmolol, bêta-blockers (bisoprolol, carvedilol, metoprolol, nebivolol),
             fingolimod
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karine Faure, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karine Faure, MD,PhD</last_name>
    <phone>0320445962</phone>
    <phone_ext>+33</phone_ext>
    <email>karine.faure@chru-lille.fr</email>
  </overall_contact>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 30, 2020</study_first_submitted>
  <study_first_submitted_qc>April 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 1, 2020</study_first_posted>
  <last_update_submitted>April 30, 2020</last_update_submitted>
  <last_update_submitted_qc>April 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Covid-19</keyword>
  <keyword>Hydroxychloroquine</keyword>
  <keyword>Dilitazem</keyword>
  <keyword>Niclosamide</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
    <mesh_term>Niclosamide</mesh_term>
    <mesh_term>Diltiazem</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

